Arch Biopartners Insider Trading

Arch Biopartners Inc. is a Canadian clinical-stage biopharmaceutical company focused on developing treatments for life-threatening inflammatory conditions. Headquartered in Toronto, Ontario, the company’s lead program targets inflammation associated with organ failure in critically ill patients, including acute respiratory distress syndrome (ARDS) and other conditions involving neutrophil-driven organ damage. Arch Biopartners is advancing its pipeline through clinical trials with a goal of addressing unmet medical needs in intensive care settings. The company is listed on the TSX Venture Exchange under the ticker ARCH.